LY-570310, a new oral hepatitis C protease inhibitor, designated a development candidate Jan. 8, 2002
Strong immune response and good tolerability for Innogenetics' E1 vaccine for hepatitis C Jan. 2, 2002
Superior efficacy of triple-antigen hepatitis B vaccine confirmed in inadequate responders Dec. 27, 2001
RSS